Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.35 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910783 | 1.00 | S1PR1 (0.42) | S1PR1OXTRMAP3K11PIP4K2APIP4K2B | |
| SCHEMBL4911977 | 0.90 | OXTR (0.40) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4904155 | 0.89 | OXTR (0.39) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4914441 | 0.89 | OXTR (0.39) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4912268 | 0.89 | OXTR (0.39) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4914201 | 0.89 | OXTR (0.39) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4912278 | 0.88 | OXTR (0.38) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4914233 | 0.88 | OXTR (0.38) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL4911982 | 0.88 | OXTR (0.38) | OXTRMAP3K11GHSRMAPK14HSD11B1 | |
| SCHEMBL14258933 | 0.87 | OXTR (0.42) | OXTRMAP3K11GHSRMAPK14HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | S1PR1 1732/4885OXTR 908/4885MAP3K11 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.